GEN2 Directed Cancer Immunotherapy Trial

NCT ID: NCT04313868

Last Updated: 2024-11-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-13
• Study Completion Date: 2023-12-12

Brief Summary

Phase 1, non-randomized, open label dose escalation clinical trial evaluating the safety of GEN2 in participants with primary & metastatic liver tumors.

Detailed Description

This clinical trial will be divided into two phases: Phase IA in which the dose, route, and schedule of the GEN2 administration is determined and Phase IB which is designed to explore the activity of GEN2 in patients of a defined or several defined tumor types and stages based on the Phase IA data of GEN2.

Phase IA is divided into three routes of administration: (a) Phase 1A.1 which explores peripheral IV infusion; (b) Phase IA.2 which investigates hepatic arterial infusion and (c) Phase IA.3 which examines intratumoral delivery.

Conditions

Hepatocellular Carcinoma; Metastatic Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Phase 1A.1: Peripheral IV

GEN2 is administered in repeating three week cycles. On week one, GEN2 is given intravenously on three consecutive days and the presence of the HSV-TK-m2 expression is monitored by \[18F\]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.

Group Type: EXPERIMENTAL

GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)

Intervention Type: DRUG

GEN2 is an investigational drug combining cytotoxic and immunotherapy.

Phase IA.2: Hepatic Artery Infusion

GEN2 is administered in repeating three week cycles. On week one, GEN2 is given as a single hepatic artery infusion (HAI) on two successive days and the presence of the HSV-TK-m2 expression is monitored by \[18F\]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.

Group Type: EXPERIMENTAL

GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)

Intervention Type: DRUG

GEN2 is an investigational drug combining cytotoxic and immunotherapy.

Phase IA.3: Intratumoral Injection

GEN2 is administered in repeating three week cycles. On week one, GEN2 is given via injection directly into the tumor lesions on one day and the presence of the HSV-TK-m2 expression is monitored by \[18F\]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.

Group Type: EXPERIMENTAL

GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)

Intervention Type: DRUG

GEN2 is an investigational drug combining cytotoxic and immunotherapy.

Interventions

GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)

GEN2 is an investigational drug combining cytotoxic and immunotherapy.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of histologically documented, advanced stage, primary or metastatic adult solid tumor(2) in the liver that are refractory to standard therapy or for which no curative standard therapy exists.
• Evidence of radiographically measurable or evaluation disease on a baseline PET-CT scan.
• All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedures must have resolved to National Cancer Institute (NCI) Common Toxicity Criteria (CTC) (Version 4.03) Grade < 1.
• Patient must be legally considered an adult in the country in which they are participating in the study.
• Last dose of antineoplastic therapy, except for hormonal therapy, must be > 21 days. External beam radiotherapy must have been <25% bone marrow-containing skeleton.
• Patients may be Hepatitis B and C positive.
• Patients may have intracranial metastases of any number if they have been brain irradiated and stable for 6 weeks. Patients may be taking anti-seizure medicines but must not be on steroids. Last dose of steroids must be >7 days.
• Karnofsky performance status must be > or = 70
• Childs-Pugh Classification Score of 7 or less
• Life Expectancy of at least 3 months
• Patients must be able to travel to alternate medical center for PET/CT scans, if necessary.
• Meet the required baseline laboratory data
• Signed informed consent indicating that they are aware of the neoplastic nature of their disease and have been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks and discomforts.
• Willing and able to comply with scheduled visits, treatment plan, and laboratory tests.

Exclusion Criteria

• Concurrent therapy with anticancer agent including any other investigational agent.
• Existing intracranial edema or CVA within 6 months of screening
• Pregnant or breast-feeding women. Female patients must agree to use effective contraception, must be surgically sterile or must be post-menopausal. Male patients must agree to use effective contraception or be surgically sterile. The definition of effective contraception will be based on the judgment of the Investigator or a designated associate. All at-risk female patients must have a negative pregnancy test within 7 days prior to start of the study treatment.
• Clinically significant cardiac disease (New York Heart Associate, Class III or IV)
• Dementia or altered mental status that would prohibit informed consent.
• Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.
• Known side effects to antivirals in the ganciclovir class
• Patients who are known to be HIV positive.
• Patients must not be taking steroids at the time of screening. Last dose of steroids must be >7 days.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GenVivo, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Priscilla B Caguioa, MD

Role: PRINCIPAL_INVESTIGATOR

St. Luke's Medical Center - Quezon City

Maria Belen E Tamayo, MD

Role: PRINCIPAL_INVESTIGATOR

Makati Medical Center

John P Querol, MD

Role: PRINCIPAL_INVESTIGATOR

The Medical City

Necy S Juat, MD

Role: PRINCIPAL_INVESTIGATOR

National Kidney and Transplant Institute

Locations

Makati Medical Center

Makati City, , Philippines

The Medical City

Pasig, , Philippines

National Kidney and Transplant Institute

Quezon City, , Philippines

St. Luke's Medical Center

Quezon City, , Philippines

Countries

Philippines

Other Identifiers

EPB-002

Identifier Type: -

Identifier Source: org_study_id